Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Articles

Alanine and Terbutaline in the Prevention of Nocturnal Hypoglycemia in IDDM

  1. Tarek Y Saleh, MD and
  2. Philip E Cryer, MD
  1. Division of Endocrinology, Diabetes and Metabolism, and the General Clinical Research Center and the Diabetes Research and Training Center, Washington University School of Medicine St. Louis, Missouri
  1. Address correspondence and reprint requests to Philip E. Cryer, MD, Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine (Box 8127), 660 South Euclid Ave., St. Louis, MO 63110.
Diabetes Care 1997 Aug; 20(8): 1231-1236. https://doi.org/10.2337/diacare.20.8.1231
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating β2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with 1DDM.

RESEARCH DESIGN AND METHODS On each of four occasions, the same individualized dose of NPH insulin (0.1–0.2 U/kg) was administered with either no treatment (control) or, in random sequence, oral treatment with a snack (240 ml of 2% milk plus one slice of toast, ∼200 kcal), alanine (40 g, plus 10 g of glucose, ∼200 kcal), or terbutaline (5.0 mg) at 2200.

RESULTS During the first half of the night (2315–0300), mean plasma glucose concentrations were higher after the snack (P < 0.02), alanine plus glucose (P < 0.01), or terbutaline (P < 0.001), compared with no treatment. During the second half of the night, mean plasma glucose levels were no different from control values (73 ± 5 mg/dl, 4.1 ± 0.3 mmol/1) after the snack (73 ± 7 mg/dl, 4.1 ± 0.4 mmol/1), tended to be higher after alanine plus glucose (96 ± 16 mg/dl, 5.3 ± 0.9 mmol/1), and were significantly higher after terbutaline (124 ± 15 mg/dl, 6.9 ± 0.8 mmol/1, P < 0.01). Nocturnal plasma glucose levels of 40 mg/dl (2.2 mmol/1) or less (which were treated with intravenous glucose) occurred on 13 occasions in seven patients in the control arm and 10 occasions in six patients in the snack arm (not significantly different from the control arm), but on only 1 occasion in the alanine-plus-glucose.arm (P < 0.02) and the terbutaline arm (P < 0.02).

CONCLUSIONS In patients with 1DDM given an evening dose of NPH insulin, a conventional bedtime snack exerts an inconsistent glycemic effect only during the first half of the night, and bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine- simulating β2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack.

  • Received March 10, 1997.
  • Accepted April 30, 1997.
  • Copyright © 1997 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

August 1997, 20(8)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Alanine and Terbutaline in the Prevention of Nocturnal Hypoglycemia in IDDM
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Alanine and Terbutaline in the Prevention of Nocturnal Hypoglycemia in IDDM
Tarek Y Saleh, Philip E Cryer
Diabetes Care Aug 1997, 20 (8) 1231-1236; DOI: 10.2337/diacare.20.8.1231

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Alanine and Terbutaline in the Prevention of Nocturnal Hypoglycemia in IDDM
Tarek Y Saleh, Philip E Cryer
Diabetes Care Aug 1997, 20 (8) 1231-1236; DOI: 10.2337/diacare.20.8.1231
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Articles

  • Phenotype of Infants of Mothers with Gestational Diabetes
  • Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes
  • Breastfeeding After Gestational Diabetes Pregnancy
Show more Original Articles

Clinical Care/Education/Nutrition

  • Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
  • An Evaluation of Methods of Assessing Impaired Awareness of Hypoglycemia in Type 1 Diabetes
  • Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes
Show more Clinical Care/Education/Nutrition

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.